stonks4u
Sign up free
ZNTL logo

ZNTL Zentalis Pharmaceuticals, Inc.

NASDAQ · Biotechnology · Healthcare

$3.56
-0.59 (-14.22%)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The …

Market Cap: $253.42Mwww.zentalis.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 13Aug 13

Quote

Day Range
$3.49 – $3.70
52-Week Range
$1.21 – $6.95
Volume
$4.57M
Market Cap
$253.42M
50-Day Avg
$4.32
200-Day Avg
$3.07
Prev Close
$4.15
Open
$3.54

Valuation & Ratios

P/E Ratio
-0.71
EPS
$-1.91
P/B Ratio
0.45
P/S Ratio
0.00
Debt/Equity
0.18
Current Ratio
6.93
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-63.4%
Return on Assets
-47.4%
FCF Yield
-129.1%
EV/EBITDA
-0.70

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-137.06M$-1.91
2024$67.42M$-165.84M$-2.33
2023$0.00$-292.19M$-4.47
2022$0.00$-236.81M$-4.48
2021$0.00$-158.72M$-3.72

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $-0.61 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.59 vs $-0.49miss
  • Tue, May 12$-0.50 vs $-0.49miss
  • Thu, Mar 26$-0.49 vs $-0.41miss
  • Mon, Nov 10$-0.37 vs $-0.49beat
  • Wed, Aug 6$-0.37 vs $-0.56beat
  • Wed, May 14$-0.67 vs $-0.67beat

Estimates and results for ZNTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ZNTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·1d ago·Negative

    Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common s…

    View source ↗